NYSE:MRX

Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Notice: This company recently went public with an IPO on Thursday, April 25th 2024. They issued 15,384,615 shares at $18.00-$21.00 per share. We will continue to update data for MRX as it becomes available.
Today's Range
$18.75
$19.29
50-Day Range
N/A
52-Week Range
N/A
Volume
1.39 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MRX stock logo

About Medicis Pharmaceutical Stock (NYSE:MRX)

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

MRX Stock News Headlines

IPOs Shine Bright in a Tough Day for Stocks
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
TLPPF Telix Pharmaceuticals Limited
AcelRx Pharmaceuticals Inc ACRX
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Ananda Developments Plc - Result of General Meeting
Boston Pharmaceuticals News
Medicis to Acquire Inamed
Medicis Stock Hits New 52-Week High (MRX)
Medicis Pharmaceutical Corp (MRX)
See More Headlines
Receive MRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Robert Roswell Chai-Onn (Age 44)
    Executive Vice President, General Counsel, Secretary, Director
  • Howard Bradley Schiller (Age 53)
    Officer, Director
  • Ryan Weldon
    Officer, Director

MRX Stock Analysis - Frequently Asked Questions

When did Medicis Pharmaceutical IPO?

Medicis Pharmaceutical (MRX) raised $300 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at $18.00-$21.00 per share.

When does Medicis Pharmaceutical's quiet period expire?

Medicis Pharmaceutical's quiet period expires on Tuesday, June 4th. Medicis Pharmaceutical had issued 15,384,615 shares in its initial public offering on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. During Medicis Pharmaceutical's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

This page (NYSE:MRX) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners